Hemostatic drug - Thrombotargets Corp

Biotecnología
Pathway screening

[ Cerrar ]

Discovery & Pipeline

Thrombotargets has developed and adapted to High Throughput Screening, a new family of biological assays capable to quantify simultaneously clot formation and clot lysis (HemostaScreen), total antioxidant capacity (OxidantScreen) and low-density lipoprotein modification (AtheroScreen). With these proven proprietary new HTS Platforms (), Thrombotargets is creating a continuously novel and promising pipeline of drug candidates.

Hemostatic drug

Know the novel hemostatic drug generation TT-103MH got through BioplatformScreen by Thrombotargets. For topical treatment of bleeding disorders.

Vein thrombosis

Thrombotargets: Science and technology that accelerates and improves the drug discovery and chemical development process in haemostasis and vein thrombosis. Know the new biotech drugs.

Superficial thrombosis

Thrombotargets is the biotech company that develops new medicines (recombinant DNA, molecular biology and small molecule drug technologies) for superficial thrombosis and other kinds of coagulation diseases.

Hemophiliacs patient

New discover to treat all kinds of bleeding in hemophiliacs' patients and healthy subjects with congenital platelet disorders and hemorrhages. Know more about TT-103MH by Thrombotargets.

Thrombotargets is developing TT- 103MH, a novel and significantly radical approach for the treatment of bleeding disorders. Using a topical formulation TT-103MH, will be effective in treating:

• Healthy subjects
• Haemophilic patients
• Inherited and acquired coagulation and platelet disorders
• Haemorrhages induced by anticoagulant and antiplatelet drugs.